CHOP Study Finds Safest Treatment for Immunodeficiency Disorder is Not Cost Effective for U.S. Patients
Nov 15, 2021
Using a model developed at CHOP, researchers find high cost of treatment most likely to prevent premature death in patients with agammaglobulinemia undermines its benefits.